Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Phlebotomy, Erythrocytapheresis · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Phlebotomy |
| 2 | ACTIVE_COMPARATOR | Erythrocytapheresis |
| Name | Type | Description |
|---|---|---|
| Phlebotomy | PROCEDURE | Removal of 500 ml whole blood |
| Erythrocytapheresis | PROCEDURE | machinal removal of erythrocytes |
Inclusion Criteria: * Hereditary haemochromatosis patients Exclusion Criteria: * Malignancies, severe arrhythmias, congestive heart failure and/or recent angina, severe liver disease, epileptic seizures preceding in last 3 months before planned treatment
Phlebotomy, Erythrocytapheresis is used for the treatment of hemochromatosis, a condition characterized by excess iron in the body. It is being developed by Atrium Therapeutics, Inc. as a therapeutic procedure to manage this condition.
Phlebotomy, Erythrocytapheresis is being developed by Atrium Therapeutics, Inc., a company listed under the ticker RNA. The company is conducting clinical research on this treatment for hemochromatosis.
Phlebotomy, Erythrocytapheresis is in Phase 3 clinical development. It is an investigational treatment for hemochromatosis and has not been approved by regulatory authorities. The Phase 3 trial has been completed.
Phlebotomy, Erythrocytapheresis has one completed Phase 3 clinical trial, identified as NCT00202436, titled 'Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy'. This trial enrolled 40 participants in the Netherlands and was active-controlled, comparing phlebotomy with erythrocytapheresis.
Phlebotomy, Erythrocytapheresis refers to a treatment approach that includes both phlebotomy and erythrocytapheresis as therapeutic options for hemochromatosis. The clinical trial NCT00202436 compares these two procedures to evaluate their effectiveness.